Search

Displaying results 1481 - 1490 of 8517 in total
  1. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    Camazepam also has less side effects, such as impaired cognition and reaction times, compared to other benzodiazepines. … In the United States camazepam is regulated as a Schedule IV controlled substance.

  2. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … As a consequence, whenever protamine sulfate use is clinically considered, careful consideration must be given as to whether the use of the agent could decrease the safety of the procedure or worsen the

  3. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

  4. Drug

    Esculin

    go.drugbank.com/drugs/DB13155
    Approved

    Esculin is found in barley. Vitamin C2 is generally considered a bioflavanoid, related to vitamin P esculin is a glucoside that naturally occurs in the horse chestnut (Aesculus hippocastanum), California Buckeye (Aesculus californica) an...

  5. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna.

  6. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative

  7. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

  8. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

  9. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

    Synonyms: bis(4-methylbenzoic acid) 4-[2-(tert-butylamino)-1-hydroxyethyl]-1,2-phenylene ester
  10. Drug

    Tacrolimus

    go.drugbank.com/drugs/DB00864
    ApprovedInvestigational

    It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide.